Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 27;44(1):5.
doi: 10.1007/s00345-025-06100-7.

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl  1 , Andrew Chilelli  2 , Rita Faria  2 , Nigel Rozario  2 , Robert Snijder  2 , Sari Stark  2 , Axel S Merseburger  3
Affiliations

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl et al. World J Urol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Amit Bahl has received honoraria from Johnson & Johnson, Astellas, Bayer, ACCORD, and AAA Pharmaceutical, and has received research grants from and has participated in advisory boards for Janssen and Bayer. Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder, and Sari Stark are employees of Astellas Pharma Europe Ltd. Axel Merseburger has received honoraria from Janssen, Astellas, Novartis, Telix, Amgen, Ipsen, Takeda, Recordati, and Bayer.

References

    1. Hu J, Aprikian AG, Vanhuyse M, Dragomir A (2022) Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer 20(1):17–24. 10.1016/j.clgc.2021.08.009 - DOI - PubMed
    1. Scailteux LM, Despas F, Balusson F, Campillo-Gimenez B, Mathieu R, Vincendeau S, Happe A, Nowak E, Kerbrat S, Oger E (2022) Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients. Br J Clin Pharmacol 88(1):336–346. 10.1111/bcp.14972 - DOI - PubMed
    1. Merseburger AS, Dornstauder E, Ohlmann CH, Aprikian A, Junker S, Hahn P, Chilelli A, Stoelzel M, Serikoff A, Spitzer SG (2025) Cardiovascular risks and survival with abiraterone vs enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer in germany: AVENGER study. Adv Ther 42(4):1919–1934. 10.1007/s12325-025-03132-8 - DOI - PMC - PubMed
    1. Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B (2015) Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 16(5):509–21. 10.1016/S1470-2045(15)70113-0 - DOI - PubMed
    1. Cella D, Ivanescu C, Holmstrom S, Bui CN, Spalding J, Fizazi K (2015) Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol 26(1):179–185. 10.1093/annonc/mdu510 - DOI - PMC - PubMed

LinkOut - more resources